Brief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
01/10/2026 12:03
BRIEF-Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk Oct 1 (Reuters) - Monte Rosa Therapeutics, Inc. GLUE.O:
MONTE ROSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FOR MRT-8102 IN GFORCE-1 PHASE 1 STUDY SHOWING NORMALIZATION OF KEY PATHOGENIC DRIVERS OF ASCVD IN SUBJECTS WITH ELEVATED CVD RISK
MONTE ROSA THERAPEUTICS, - TO INITIATE MULTIPLE PHASE 2 STUDIES OF MRT-8102 IN HIGH UNMET NEED INDICATIONS
Source text: ID:nGNX8DpyQl
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million